Department of Radiation Oncology, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstraße 27, 91054, Erlangen, Germany.
Department of Prosthodontics, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glückstraße 11, 91054, Erlangen, Germany.
Strahlenther Onkol. 2019 Jun;195(6):482-495. doi: 10.1007/s00066-018-1415-y. Epub 2019 Jan 4.
The aim of this retrospective study was to evaluate the clinical outcome of a previously defined low-risk patient population with completely resected (R0) squamous cell carcinoma of the oral cavity, oropharynx, larynx (pT1-3, pN0-pN2b), hypopharynx (pT1-2, pN0-pN1), and the indication for postoperative radio(chemo)therapy.
According to predefined criteria, 99 patients with head and neck squamous cell carcinoma (SCC) who were treated at our institution from January 1, 2005 to December 31, 2014, were available for analysis. The Kaplan-Meier method was used for calculating survival and incidence rates. For univariate comparative analysis, the log-rank test was used for analyzing prognostic clinicopathologic parameters.
Median follow-up was 67 months. Cumulative overall (OS) and disease-free survival (DFS) were 97.9%/94.7%/88.0% and 96.9%/92.6%/84.7% after 1, 2, and 5 years, respectively. Cumulative incidence of loco-regional recurrence (LRR), distant metastases (DM), and second cancer (SC) were 1.0%/1.0%/4.9%, 0.0%/3.4%/5.8%, and 2.1%/4.2%/13.1%, respectively. In univariate comparative analysis, location of the primary tumor in the oropharynx was a significant predictor for increased OS (p = 0.043) and DFS (p = 0.048).
Considering the low disease relapse rates and high rates of therapy-induced late side effects, as well as the increased risk of developing SC, a prospective multicentric trial investigating de-escalation of radiotherapy in this clearly defined low-risk patient population was started and is still recruiting patients (DIREKHT-Trial, NCT02528955).
本回顾性研究旨在评估完全切除(R0)的口腔、口咽、喉(pT1-3、pN0-pN2b)、下咽(pT1-2、pN0-pN1)鳞状细胞癌的经术前定义的低危患者人群的临床结局,以及术后放(化)疗的适应证。
根据预设标准,对 2005 年 1 月 1 日至 2014 年 12 月 31 日在本机构治疗的 99 例头颈部鳞状细胞癌(SCC)患者进行分析。采用 Kaplan-Meier 法计算生存率和发病率。单变量比较分析采用对数秩检验分析预后临床病理参数。
中位随访时间为 67 个月。1、2 和 5 年时的累积总生存率(OS)和无病生存率(DFS)分别为 97.9%/94.7%/88.0%和 96.9%/92.6%/84.7%。局部区域复发(LRR)、远处转移(DM)和第二原发癌(SC)的累积发生率分别为 1.0%/1.0%/4.9%、0.0%/3.4%/5.8%和 2.1%/4.2%/13.1%。单变量比较分析显示,原发肿瘤位置在口咽是 OS(p=0.043)和 DFS(p=0.048)的显著预测因素。
考虑到疾病复发率低、治疗相关晚期副作用发生率高,以及发生第二原发癌的风险增加,一项针对该明确低危患者人群放疗降阶的前瞻性多中心试验已经启动,目前仍在招募患者(DIREKHT 试验,NCT02528955)。